NCT05594290View on ClinicalTrials.gov

Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

Retifanlimab

Retifanlimab i.v. 500 mg day 1

DRUG

Cisplatin

Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)

DRUG

Etoposide

Etoposide 100 mg/sqm iv. day 1, 2, 3

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan

All Listed Sponsors
lead

Gruppo Oncologico del Nord-Ovest

OTHER